Emerging Insights into the Distinct Pharmacological Mechanisms of Buprenorphine

Morphine, an agonist of the μ-opioid receptor (μOR), extracted from Papaver somniferum (opium poppy), is an effective analgesic for moderate to severe pain. However, prolonged or inappropriate use of morphine can lead to the development of Opioid Use Disorder (OUD). In contrast, buprenorphine is a high-affinity partial μOR agonist and one of the safest opioids, widely used to treat OUD. This study investigates how specific functional groups of buprenorphine contribute to its strong receptor binding and partial agonist activity. Using alchemical free-energy methods and molecular dynamics simulations, we propose that the 2-hydroxy-3,3-dimethylbutan-2-yl moiety at the C7 position of buprenorphine contributes most to its enhanced binding affinity, while the N-cyclopropylmethyl group underlies its partial agonist activity. Moreover, radioligand competitive binding assays revealed that morphine and buprenorphine have nonclassical μOR binding profiles: morphine displays negative cooperativity (binding reduces affinity at the second site), while buprenorphine shows positive cooperativity (binding increases affinity at the second site). These two binding sites are attributed to the two protomers of the μOR homodimer. Molecular dynamics simulations suggest that the tert-butyl group of buprenorphine promotes an inward shift of TM 5 by interacting with L22145.52 in ECL 2, while the ether bridge causes steric repulsion with I2986.51 and V3026.55, driving an outward displacement of TM 6. Consequently, the initial binding of buprenorphine to the first protomer induces a conformational rearrangement that is transmitted to the second protomer via the TM5/6 homodimerization interface. These movements act as a positive allosteric mechanism, reshaping the binding pocket of the second protomer to favor an optimal fit of buprenorphine (positive cooperativity). Finding the key molecular characteristics of buprenorphine that drive its beneficial effects is essential to guiding the design of future drugs.